Interesting Engineering on MSN1h
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatmentFirst-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
News Medical on MSN1d
Diabetes drugs may boost brain health but experts warn of risksRAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...
A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback